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Introduction: T1D is a disease that leads to pancreatic beta cells death, resulting in 
complete insulin loss. Type 1diabetes (T1D) occurs as a result of autoimmunity which takes 
insulin producing β cells as a target and is considered as a metabolic disorder causing 
hyperglycemia resulting from a serious loss of endogenous insulin production. Using 
cadaveric islets as a replacement therapy was done to reverse diabetes. Many various 
progenitor cell types have been found in the peripheral blood mononuclear cell (PBMC) 
fraction denoting those PBMCs may have the ability to differentiate into many mature 
functional cell types in certain microenvironments. It is settled that circulating peripheral 
blood mononuclear cells (PBMC) contain germinal cell population which can share in the 
regeneration of tissues in different organs Materials and methods: 2 groups of type I 
diabetes patients had been monitored in a private clinic, number 40 each group, with 35 
females and 45 males. Lied between 8-25 years old with 4-7 years of diabetes onset. The 
first group was on insulin therapy and they received peripheral blood mononuclear cells 
concentrate directly in the dorsal pancreatic artery. The second group was only on insulin 
injection. Results: The results show a significant increase in c peptide levels after direct 
injection of peripheral blood mononuclear cells in the dorsal pancreatic artery with p-
value less than 0.0001. Conclusion: The peripheral blood mononuclear cells can induce 
beta cell regeneration and increase beta cell mass which is detected by an increase in c 
peptide levels. 
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INTRODUCTION 
T1D is a disease that leads to pancreatic 
beta cells death, resulting in complete 
insulin loss. Autoimmune-mediated 
destruction of beta cells (type1a) 
represents most type 1diabetes cases 
whereas idiopathic destruction of beta 
cells (type 1b) represents only a minority 
of cases. T1D accounts for 5–10% of the 
total cases of diabetes worldwide [1]. The 
human leukocyte antigen (HLA) complex 
on chromosome 6 is the most serious of 
the genes involved in susceptibility (and 
resistance) to T1D, specifically, the HLA 
class II. Two susceptibility haplotypes in 
the HLA class II region are now 
considered the principal susceptibility 
markers for T1D41 [2]. Whereas about 
5% or less of peoples with HLA-
conferred genetic susceptibility actually 
develop clinical disease, it’s interesting to 
know that about 95% of children with 
T1D have one or both vulnerability 
haplotypes [3]. There is a strong co-
relation between T1D and other 
autoimmune diseases, like autoimmune 
thyroid disease [4]. It is settled that these 
autoimmune diseases are caused by genes 
within the major histocompatibility 
complex [5]. It is considered that Genes 
alone couldn’t result in T1D; there is a 
role also for the environment. There is 
strong evidence that not all persons who 
have high-risk genes get T1D. It is also 
evidenced that, most people with high-
risk HLA class II genes (DR4/DQ8 and 
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DR3/DQ2) do not get T1D. There must 
be at least one environmental factor 
exciting the autoimmune process before a 
clinical diagnosis of hyperglycemia and 
T1D. It is considered that islet 
autoantibodies the first laboratory 
evidence of beta cell autoimmunity) in 
high-risk individuals happen below 2 
years of age [6]. Denoting that an 
environmental factor is present in early 
life. Viral infection is considered as the 
most studied environmental factor 
causing type 1 diabetes [7]. Till this 
moment, insulin is considered the only 
therapy for the treatment of T1D. Until 
now, there is no treatment option to keep 
endogenous insulin production. All 
clinical trials failed to slow the 
progression of the disease or inhibit its 
onset. It is thought that specific therapies 
targeting the immune system are needed 
to prevent type1 diabetes [8]. It is 
considered that HLA DQ8 which is 
present in about 60% of all T1D patients 
leads to considerable risk for disease 
development [9]. Using cadaveric islets as 
a replacement therapy was done to 
reverse diabetes [10] with some patients 
preserving insulin independence at 5 
years). But, healthy pancreatic islets are 
not available for common use [11]. It is 
evidenced that rodent βcell mass could 
change in response to various 
circumstances. For example, βcell mass 
increases during pregnancy, due to both 
βcell hyperplasia and hypertrophy 
[12].But after delivery, β cell apoptosis 
rate increases resulting in the return of β 
cell mass to normal [13]. It is thought that 
changes occurring in pregnancy could 
help the pregnant female to adapt with 
hyperglycemia by increasing insulin. 
Also, various conditions of insulin 
resistance resulting in increased β cell 
mass [14]. It is evident that new insulin-
producing β cells are created from 
endocrine progenitor cells during 
embryonic development of the pancreas 
[15]. These progenitor cells arise from the 
pancreatic epithelium and then 
differentiate into various hormone‐
producing cells to make the islets of 
Langerhans [16]. It is considered that β 
cell formation which is shifted postnatally 
from an embryonic mode based on 
progenitor cells to simple duplication’ 
mode is reversible and consequently 
under certain conditions, the embryonic 
mode is motivated. Which give a good 
therapeutic option, even for type 
1diabetes patients in spite of completely 
losing their β cells, by keeping the 
possibility of stimulating the embryonic 
mode for β cell genesis? It has been 
thought that adult pancreatic ducts could 
act as ‘facultative progenitor cells’ in 
which, they could maturate into new β 
cells through the embryonic pathway 
when subjected to certain injury 
circumstances, a process named [17]. It is 
also thought that new β cells could 
originate from acinar cell trans 
differentiation [18], or bone marrow-
derived cells [19]. Stem cells are cells 
that are able to construct any human 
tissue, and so these cells have a great 
possibility for tissue regeneration. To say 
that the cells are “stem cells,” they should 
have a fundamental character. In which, 
stem cells must be able to self- renew in 
an unlimited way to give cells as same as 
the original cell. What happens is like 
cancer cells which split in an organized 
way but the difference is that stem cell 
division is highly organized. They can 
result in a specialized cell type [20]. 
 
Stem cells are sorted into two categories 
relied on their biologic character - 
pluripotent and multipotent stem cells. 
Pluripotent stem cells can give rise to all 
cell types in the body. In natural 
development, pluripotent stem cells are 
existed just in the embryo before giving 
rise to the more specialized multipotent 
stem cells that could differentiate into 
particularized cells. In the other side, 
more limited multipotent stem cells have 
several subtypes: some could be only 
cells of a particular germline and the 
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other cells, could be of a special 
character. We can say that pluripotent 
cells could give rise to any cell of the 
body by differentiating into multipotent 
stem cells that could pass with a series of 
divisions into more limited specialized 
cells [21]. It is considered that most adult 
tissues contain stem cells which are able 
to differentiate into a specific tissue. 
Many various progenitor cell types have 
been found in the peripheral blood 
mononuclear cell (PBMC) fraction 
denoting that PBMCs may have the 
ability to differentiate into many mature 
functional cell types in certain 
microenvironments [22]. It is considered 
that PBMCs can differentiate along 
different lineages relying on culture 
conditions or where it will be transplanted 
[23]. Blood is considered the most 
appropriate source in which can get stem 
cells and we can get from patients in 
whom it can be saved for future 
utilization. Fortunately, stem cells can be 
developed in culture and can be 
stimulated to convert to pluripotent stem 
cells (iPSCs) [24]. Endothelial progenitor 
cells which are present in BM and 
peripheral blood have the ability to 
convert to mature endothelial cells (ECs) 
for revascularization, and so present a 
substantial stimulatory pathway for 
angiogenesis [25].  Granulocyte colony-
stimulating factor multiple injections can 
assemble progenitor cells from the BM 
and moving them to peripheral blood 
circulation [26]. Mesenchymal stem cells 
which are derived from peripheral blood 
mononuclear cells could stimulate 
angiogenesis at sites with ischemia, and 
decrease the ischemic deterioration [27]. 
It is considered that the peripheral blood 
mononuclear cell population contains 
various progenitor cells. Some studies 
declared that comparatively few 
hematopoietic stem cells are present in 
the peripheral blood sharing in the 
conservation of hematopoietic function 
[28]. Fortunately, fibrocytes, which is 
considered as a mesenchymal cell, were 
found in cultures derived from the 
peripheral blood mononuclear cell of the 
peripheral blood [29]. Fibrocytes in the 
peripheral blood were considered to have 
great differentiation ability under certain 
conditions. Tissue Injury is considered to 
be the cause for moving these progenitor 
cells to injury sites in which sharing in 
the regeneration of these tissues [30]. It is 
settled that circulating peripheral blood 
mononuclear cells (PBMC) contain 
germinal cell population which can share 
in the regeneration of tissues in different 
organs [31]. PBMCs contain Cells which 
comprise CD14+ monocytes which are 
created from hematopoietic stem cells in 
the bone marrow and consist of about 
10% of white blood cells in the peripheral 
circulation. It also considered that 
Monocytes could differentiate and 
convert to multiple phagocytes [32].It is 
suggested that mononuclear cells could 
differentiate into other cell types beside 
phagocytes, like skeletal muscles and 
bone, which making them a possible 
choice for tissue repair [33]. To get new 
insulin-producing cells, we can use 
peripheral blood mononuclear cells as an 
origin because these cells may be capable 
of conversion into unrelated cell types. 
There are only two studies so far which 
used monocytes as the source for insulin-
producing cells [34]. Based on previous 
studies, Monocytes could be de-
differentiated in vitro when Interleukin-3 
(IL-3) and Macrophage Colony-
stimulating Factor (M-CSF) are present, 
and so we can say that this process can 
transform peripheral blood mononuclear 
cells to Progenitor Cells of Monocytic 
Origin (PCMOs). Fortunately, when 
Epidermal Growth Factor (EGF) and 
Hepatocyte Growth Factor (HGF) are 
present, PCMOs could be moreover 
cultured in vitro in for 4-6 days, 
consequently, they were able to express 
pancreatic genes yielding little amounts 
of insulin [35]. Peripheral blood 
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mononuclear cells could be converted to 
cells that produce sufficient insulin to 
correct blood glucose [36]. And so we can 
say that Peripheral blood mononuclear 
cells could be used for regeneration of 
pancreatic beta cells as autologous 
transplants in which are removed from a 
person, stored, and later given back to 
that same person [37]. It was seen that 
when autologous bone marrow stem cells 
are injected directly into the pancreas via 
the gastroduodenal artery in T2DM, there 
was a proven success [38]. 
 
MATERIALS AND METHODS 
2 groups of type I diabetes patients had 
been monitored in a private clinic, 
number 40 each group, with 35 females 
and 45 males after written consent of all 
patients. All the patients Lied between 
18-25 years old with 8-12 years of 
diabetes onset. The first group was on 
insulin therapy in the form of Lantus once 
daily and Apidra 3 times daily and they 
received auto peripheral blood 
mononuclear cells concentrate directly in 
the dorsal pancreatic artery . 
The second group was only on insulin 
injection in the form of Lantus once daily 
and Apidra 3 times daily. In the first 
group; we measured postprandial c 
peptide levels before and after 3 months 
of direct injection of peripheral blood 
mononuclear cells in the dorsal pancreatic 
artery. In the second group, we measured 
c peptide levels at the beginning of the 
trial and after 3 months. 
 
PREPARATION OF PERIPHERAL 
BLOOD MONONUCLEAR CELLS 
 All the patients in the 2 groups received 
granulocyte colony stimulating factor 
drug (Filgrastim) daily for 5 days to 
stimulates the bone marrow to produce 
granulocytes and stem cells and release 
them into the bloodstream. Filgrastim is a 
human granulocyte colony stimulating 
factor (G-CSF) produced by recombinant 
DNA technology, which regulates the 
production of neutrophils within the bone 
marrow. 
 Filgrastim was given by subcutaneous 
injection. 
 Filgrastim was given on a daily basis 
for 5 days. 
 Filgrastim was refrigerated. 
 Removed from refrigerator 30 minutes 
before injection. 
 Not shaken and Protected from light. 
 Was given by a adose of 10 
mcg/kg/day SC. 
 No side effects were detected in the 
patients. 
 The blood was collected and 
manipulated in ibn Sina laboratory 
centre. 
 About 60 cm blood from a peripheral 
vein was collected in a heparinized 
tube. 
 Then mixed with equal volume of 
phosphate buffered saline. 
 Ficoll-Hypaque solution was used for 
separation of monocytes. 
 It was placed at the bottom of the 
tube. 
 Using 5 ml Ficoll-Hypaque for 10 ml 
blood/PBS mixture. 
 Centrifuging for 30 min at 2000 rpm. 
 The upper layer that contains the 
plasma and most of the platelets were 
removed by a pipet. 
 The mononuclear cell layer was 
transmitted to another centrifuge tube. 
 Then cells were washed by adding 
phosphate buffered saline and 
centrifuging 10 min at 1300 rpm. 
 And then mononuclear cells were 
resuspended with platelet-rich plasma 
and counted. 
 The injection was done in tanta 
radiology centre by direct injection in 
the dorsal pancreatic artery of about 
30 cm concentrate of mononuclear 
cells with prp. 
 
RESULTS 
Fig 1, 2 groups of patients showing 
significant increase in c peptide levels 
after mononuclear cells. 
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Figure 2: Group1 showing significant increase in c peptide levels after mononuclear cells. 
 
 
Figure 3: Group 1 showing significant increase in c peptide levels after mononuclear cells. 
 
 
Figure 4:  Group 2 of patients showing non significant change in c peptide levels. 
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Fig 5:  Group 2 patients showing non-significant change in c peptide levels 
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For analysis of data we used unpaired t test 
In the first group of patients (as seen in 
figures 1, 2,3and tables 1 and 2) on insulin 
and mononuclear cells injection directly in 
dorsal pancreatic artery; P value; <0.0001 
which is significantly different 
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In the second group of patients (as in fig 1, 
4 and 5 and tables 1 and 3) who were on 
insulin only P value; 0.3427 which is non-
significant
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The results shows significant increase in c 
peptide levels after direct injection of 
peripheral blood mononuclear cells in 
dorsal pancreatic artery after stimulation 
by granulocyte colony-stimulating factor 
(G-CSF) with p value less than 0.0001 as 
seen in( fig 1,2 and 3). With non-
significant change in c peptide levels in the 
second group who were on insulin only 
and who received granulocyte colony-
stimulating factor (G-CSF)also with p 
value; 0.3427 which is non-significant. 
 
DISCUSSION 
Type 1 diabetes (T1D) occurs as a result 
of autoimmunity which takes insulin 
producing β cells as a target and is 
considered as a metabolic disorder 
causing hyperglycemia resulting from a 
serious loss of endogenous insulin 
production .in the past type1diabetes was 
considered as a disease of children but 
now it is evidenced that type 1 diabetes 
could occur even in older peoples [39]. It 
is settled that more than 30.000 persons 
getting type 1 diabetes per year in U.S. 
and the incidence of type1 diabetes all 
over the world is elevated to about 28% 
per week [40]. Unfortunately, most 
patients with type1diabetes don't get 
glycemic control in spite of insulin 
therapy and complications of type 1 
diabetes occur frequently. Type 1 diabetes 
put great physical and physiological stress 
on patients and their relatives also lead to 
an elevated risk of morbidity and 
mortality. For all of these reasons, there 
must be new therapies to cure type 
1diabetes, targeting beta cell regeneration 
and stopping the immune system from 
attacking beta cells [41]. It is evidenced 
that peripheral blood mononuclear cells 
(PBMCs), are able to liberate 
considerable amounts of active paracrine 
factors that make advantageous repair 
effects. The PBMC were used in a 
successful way for the treatment of some 
serious diseases like myocardial 
infarction, heart failure, stroke [42]. In 
this study, we used peripheral blood 
mononuclear cells to evaluate their effect 
on pancreatic beta cells regeneration and 
on c peptide levels, by infusion these cells 
directly in the dorsal pancreatic artery and 
comparing them with the group of 
patients on insulin therapy only.  
 
There are 2 limitations of this study; the 
first the small number of patients but we 
can explore the results to the general 
population, the second limitation is 
whether the results are transient or 
persistent. As type 1 diabetes is a serious 
disease and there are many stresses on 
patients and their relatives, we hope to 
find a new conclusive therapy. The results 
of our study show that autologous 
peripheral blood mononuclear cells which 
are easy to get may be a good choice for 
pancreatic beta cells regeneration and 
consequently for type 1 diabetes cure. 
Further large-scale studies and clinical 
trials are required to verify our results. 
 
CONCLUSION 
As stem cells are considered as being able 
to construct any human tissue, and have a 
great possibility for tissue regeneration, 
and as Peripheral blood is a large 
accessible source of adult stem cells. 
peripheral blood mononuclear cells which 
are created from hematopoietic stem cells 
in the bone marrow and consist of about 
10% of white blood cells in the peripheral 
circulation could differentiate into other 
cell types beside phagocytes, like skeletal 
muscles and bone, which making them a 
possible choice for tissue repair. The 
peripheral blood mononuclear cells can 
induce beta cell regeneration and increase 
beta cell mass which is detected by an 
increase in c peptide levels which may 
add a new choice for type 1 diabetes 
treatment. 
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